sun pharma receives usfda approval for bromsiteâ„¢ [company update]

Upload: shyam-sunder

Post on 07-Jul-2018

216 views

Category:

Documents


0 download

TRANSCRIPT

  • 8/18/2019 Sun Pharma Receives USFDA Approval For BromSiteâ„¢ [Company Update]

    1/3

    Sun Pharmaceutical Industries Ltd.,SUN HOUSE, CTS No. 201 !1,"estern E#$ress Hi%h&a', (ore%aon )E*,+umai -000/, IndiaTel. )122* -/2- -/2- 3a#. )122* -/2- -/-/CIN L2-2/0(41/PLC01050&&&.sun$harma.com 

    6e%istered O77ice SP86C, Tandal9a, :adodara ; /0 020 India.Cor$orate O77ice SUN HOUSE, CTS No. 201 !1, "estern E#$ress Hi%h&a', (ore%aon )E*, +umai -000/, India.

    9 April 2016.

    National Stock Exchange of India Ltd,Exchange Plaza, 5th Floor,Plot No. C/1, G lock,andra !"rla Co#$lex,andra %Ea&t',("#)ai * + 51.

    SE Li#ited,(arket -$eration& e$t.Phiroze ee0ee)ho 2o3er&,alal Street,("#)ai 4 + 1.

    ear Sir&,

    Sub: Press Release

    e are $lea&ed to enclo&e here3ith o"r Pre&& 6elea&e relating to 7SF8 8$$ro9al For ro#Site:, 3hich3e &hall )e relea&ing after &ending thi& letter to o". 2hi& i& for o"r infor#ation and record.

    2hanking o",

     ;o"r& faithf"ll,For S"n Phar#ace"tical Ind"&trie& Ltd

     8&hok I. h"taCo#$liance -fficer

    Encl< a& a)o9e

  • 8/18/2019 Sun Pharma Receives USFDA Approval For BromSiteâ„¢ [Company Update]

    2/3

    Sun Pharmaceutical Industries Ltd.SUN HOUSE, CTS No. 201 !1,"estern E#$ress Hi%h&a', (ore%aon )E*,+umai -000/, IndiaTel. )122* -/2- -/2- 3a#. )122* -/2- -/-/CIN L2-2/0(41/PLC01050&&&.sun$harma.com 

    6e%istered O77ice SP86C, Tandal9a, :adodara ; /0 020. IndiaCor$orate O77ice SUN HOUSE, CTS No. 201 !1, "estern E#$ress Hi%h&a', (ore%aon )E*, +umai -000/, India.

    FOR IMMEDIATE RELEASE 

    Sun Pharma Receives USFDA Approval For BromSite™

    First NSAID approved for prevention of ocular pain in patients undergoing cataract surgery  

    Mumai! April "#! $"%&'  Sun Pharma (Reuters: SUN!"# !loom$erg: SUNP IN# NS%: SUNP&AR'A# !S%:)*+,# Sun Pharmaceutical Industries -td and includes its su$sidiaries or associate companies. today announcedthat one of its /holly o/ned su$sidiaries has received approval from USFDA for its Ne/ Drug Application (NDA.related to !romSite0 ($romfenac ophthalmic solution. 11+2 for the treatment of postoperative inflammationand prevention of ocular pain in patients undergoing cataract surgery !romSite0 is the first non3steroidal anti3

    inflammatory drug (NSAID. approved $y the USFDA to prevent pain and treat inflammation in the eye for patientsundergoing cataract surgery4 other NSAIDs in this class are currently indicated for the treatment of inflammationand reduction of pain

    !romSite0 developed $y InSite 5ision# is the first $romfenac ophthalmic solution formulated in DuraSite0# apolymer3$ased formulation that can $e used to improve solu$ility# a$sorption# $ioavaila$ility# and residence time ascompared to conventional topical therapies Sun Pharma ac6uired InSite 5ision in Novem$er )1, and is li7ely tocommerciali8e !romSite0 through its ne/ly formed# US3$ased division# Sun "phthalmics# in the second half of)1,9 As per I'S 'A ;anuary )1,9# the US NSAID "phthalmic mar7et gre/ $y *11mn in sales and a$out * million prescriptions# providing an attractive mar7et for Sun Pharma to participate

    Sun "phthalmics has crossed a 7ey $usiness milestone through !romSite?s approval Sun "phthalmics targets to

    provide eye care practitioners products that enhance their practice patterns and treatment options and to deliverthose products through its uni6ue# concierge level approach to customer care @ith !romSite?s approval andadditional late3stage candidates in its pipeline# Sun "phthalmics is strongly positioned to offer a range of $eneficialproducts and esta$lish itself as a respected and trusted partner

    In t/o multi3center# randomi8ed# place$o3controlled Phase3 studies# a significantly higher proportion of !romSite3treated patients /ere pain3free at Day , post3surgery (++2 and

  • 8/18/2019 Sun Pharma Receives USFDA Approval For BromSiteâ„¢ [Company Update]

    3/3

    Sun Pharmaceutical Industries Ltd.SUN HOUSE, CTS No. 201 !1,"estern E#$ress Hi%h&a', (ore%aon )E*,+umai -000/, IndiaTel. )122* -/2- -/2- 3a#. )122* -/2- -/-/CIN L2-2/0(41/PLC01050&&&.sun$harma.com 

    6e%istered O77ice SP86C, Tandal9a, :adodara ; /0 020. IndiaCor$orate O77ice SUN HOUSE, CTS No. 201 !1, "estern E#$ress Hi%h&a', (ore%aon )E*, +umai -000/, India.

     Aout Sun Pharmaceutical In(ustries Lt() *+I, - L$.$/"01%##/PL+"%#"2"3'

    Sun Pharma is the /orldJs fifth largest specialty generic pharmaceutical company and IndiaJs top pharmaceutical company Avertically integrated $usiness# economies of scale and an e=tremely s7illed team ena$le us to deliver 6uality products in a timelymanner at afforda$le prices It provides high36uality# afforda$le medicines trusted $y customers and patients in over ,1countries across the /orld Sun PharmaJs glo$al presence is supported $y * manufacturing facilities spread across 9continents# RKD centres across the glo$e and a multi3cultural /or7force comprising over 1 nationalities he consolidatedrevenues for ,) months ending 'arch )1, /ere appro=imately US> * $illion# of /hich US contri$uted US> )) $illion InIndia# the company enCoys leadership across ,) different classes of doctors /ith 1 $rands featuring amongst top 11pharmaceutical $rands in India Its footprint across emerging mar7ets covers over ,11 mar7ets and 9 mar7ets in @estern%urope Its Llo$al Honsumer &ealthcare $usiness is ran7ed amongst op ,1 across * glo$al mar7ets Its API $usiness footprint

    is strengthened through ,* /orld class API manufacturing facilities across the glo$e Sun Pharma fosters e=cellence throughinnovation supported $y strong RKD capa$ilities comprising a$out )#111 scientists and RKD investments of over +2 of annualrevenues For further information please visit ///sunpharmacom K follo/ us on /itter MSunPharma-ive 

    +ontacts

    USAHorporate HontactSanCay 'aliec7al

    'edia Hontact'i7e %lofer O Pascale Hommunications

    el Direct , +) +*39+ el Direct , *